InvestorsHub Logo

lasers

10/07/17 2:02 PM

#6785 RE: hurley cruppers #6782

$VCEL may that choice of:

Consistent with its previously disclosed strategy to focus investments on its high-growth commercial business, the Company does not plan to conduct any additional clinical studies for ixmyelocel-T unless fully funded by a partner.



However $VCEL has several options of funding a PH3 trial IF it chooses to including its own cash in 2018 as the monies continue to roll into $VCEL treasury from sales of Epicel and Maci. in the USA, UK, and Europe. Very soon additional monies will flow in from ICT from Asian sales in China, South Korea and Singapore. So what will $VCEL do with all the cash build up in its treasuries?